Theriva Biologics, Inc.

Snapshot

Theriva is a clinical-stage biotech with no revenue, a $25.2M net loss in FY 2025, and free cash flow of negative $16.7M.

What's Happening Right Now

• Mon 2nd Nov '26 · Asset sale: On Nov 2, 2026, Theriva sold its SYN-004 antibiotic-degrading enzyme portfolio to Biossil Labs for $350,000 upfront plus up to $91M in contingent milestones and royalties, making VCN-01 its lead program.
• Tue 20th Oct '26 · Share vote/dilution: Theriva called a Nov 18, 2026 special meeting to raise authorized shares to 500 million and re-approve warrants covering 16.18 million shares (roughly 35% of shares outstanding) after a prior proxy disclosure error triggered shareholder litigation; three earlier quorum attempts failed.
• Wed 30th Sep '26 · Trial data published: On Sep 30, 2026, Theriva announced peer-reviewed publication in Nature Medicine of VIRAGE Phase 2b results showing improved survival for VCN-01 added to chemotherapy in metastatic pancreatic cancer, with a follow-on VIRAGE2 dosing trial underway.
• Tue 11th Aug '26 · Q2 earnings: Theriva's Q2 2026 results showed a $3.2M net loss (improved from $13.1M a year earlier), $11.3M in cash as of June 30, 2026, and the first patient dosed in the VIRAGE2 Phase 2a trial.
• Thu 6th Aug '26 · Trial dosing: On Aug 6, 2026, Theriva dosed the first patient in the VIRAGE2 Phase 2a trial evaluating more frequent VCN-01 dosing in metastatic pancreatic cancer, with initial data expected by Q3 2027.
• Tue 30th Jun '26 · ATM sale: Sold $2.30M net / 10.20M shares through its at-the-market program, as stated for Jan 1, 2026 to Jun 30, 2026.
• Tue 31st Mar '26 · ATM sale: Sold $2.30M net / 10.20M shares through its at-the-market program, as stated for Jan 1, 2026 to Mar 31, 2026.
• Wed 31st Dec '25 · ATM sale: Sold $6.50M net / 17.29M shares through its at-the-market program, as stated for Oct 1, 2025 to Dec 31, 2025.